-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Boston Scientific Corporation's Income Statement
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue |
|
$11.89 B | $12.68 B | $14.24 B | $16.75 B | $20.07 B |
| Cost of Revenue |
|
$4.43 B | $4.97 B | $5.41 B | $6.48 B | $6.22 B |
| Gross Profit |
|
$7.46 B | $7.71 B | $8.83 B | $10.27 B | $13.85 B |
| Research & Development |
|
$1.20 B | $1.32 B | $1.41 B | $1.62 B | $2.05 B |
| Selling,General & Administrative |
|
$4.29 B | $4.52 B | $5.19 B | $5.98 B | $6.89 B |
| Operating Expense |
|
$5.54 B | $5.89 B | $6.65 B | $7.63 B | $9.88 B |
| Operating Income |
|
$1.92 B | $1.82 B | $2.18 B | $2.64 B | $3.97 B |
| Net Income |
|
$1.04 B | $698.00 M | $1.59 B | $1.85 B | $2.89 B |
Boston Scientific Corporation's Balance Sheet
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$1.93 B | $928.00 M | $865.00 M | $414.00 M | $2.05 B |
| Inventories |
|
$1.61 B | $1.87 B | $2.48 B | $2.81 B | $2.94 B |
| Total Current Assets |
|
$6.32 B | $5.76 B | $6.51 B | $6.92 B | $8.79 B |
| Property,Plant and Equipment |
|
$2.69 B | $2.83 B | $3.30 B | $3.74 B | $4.50 B |
| Goodwill |
|
$11.99 B | $12.92 B | $14.39 B | $17.09 B | $18.28 B |
| Total Assets |
|
$32.23 B | $32.47 B | $35.14 B | $39.40 B | $43.67 B |
| Total Liabilities |
|
$15.61 B | $14.90 B | $15.61 B | $17.39 B | $19.20 B |
| Retained Earnings |
|
-$1.39 B | -$750.00 M | $819.00 M | $2.67 B | $5.57 B |
| Total Shareholder Equity |
|
$16.62 B | $17.57 B | $19.28 B | $21.77 B | $24.23 B |
| Common Stock |
|
$17.00 M | $17.00 M | $17.00 M | $17.00 M | $17.00 M |
Boston Scientific Corporation's Cash flow
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$1.09 B | $1.14 B | $1.20 B | $1.27 B | $1.37 B |
| Dividends Payout |
|
-$55.00 M | -$55.00 M | -$28.00 M | - | - |
| Capital Expenditures (Capex) |
|
-$554.00 M | -$612.00 M | -$800.00 M | -$790.00 M | -$876.00 M |
| Free Cash Flow (FCF) |
|
$1.32 B | $914.00 M | $1.70 B | $2.65 B | $3.66 B |
Boston Scientific Corporation's Profitability
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Gross Profit |
|
$7.46 B | $7.71 B | $8.83 B | $10.27 B | $13.85 B |
| Gross Profit Margin (%) |
|
62.76% | 60.83% | 62.02% | 61.31% | 69.01% |
| Operating Income |
|
$1.92 B | $1.82 B | $2.18 B | $2.64 B | $3.97 B |
| Operating Income Margin (%) |
|
16.17% | 14.38% | 15.32% | 15.73% | 19.78% |
| Net Income |
|
$1.04 B | $698.00 M | $1.59 B | $1.85 B | $2.89 B |
| Net Income Margin (%) |
|
8.75% | 5.50% | 11.19% | 11.07% | 14.38% |
| EBITDA |
|
$2.52 B | $2.74 B | $3.45 B | $3.94 B | $3.73 B |
| EBITDA Margin (%) |
|
21.18% | 21.61% | 24.25% | 23.51% | 18.60% |
Boston Scientific Corporation's Ratios
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
6.26% | 3.97% | 8.26% | 8.52% | - |
| Return on Assets (ROA) |
|
3.23% | 2.15% | 4.53% | 4.71% | - |
| Debt to Equity |
|
56.85% | 52.82% | 49.23% | 51.20% | 51.24% |
| Debt to total asset |
|
29.32% | 28.59% | 27.02% | 28.30% | 28.43% |
| Enterprise value to revenue |
|
5.72 | 5.88 | 6.50 | 8.49 | 0.00 |
| Enterprise value to EBITDA |
|
26.98 | 27.20 | 26.82 | 36.10 | 0.00 |
| Enterprise value |
|
$67.95 B | $74.54 B | $92.62 B | $142.17 B | - |
| Tax Rate (%) |
|
3.35% | 38.83% | 19.80% | 19.11% | 14.56% |
Frequently Asked Questions
